Browse Category

Pharmaceuticals News 31 December 2025 - 1 January 2026

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

NEW YORK, January 1, 2026, 3:46 PM ET — Market closed. Corcept Therapeutics (CORT.O) shares ended the last U.S. session down 50.4% at $34.80 after the Food and Drug Administration declined to approve the company’s drug relacorilant for a rare hormonal-disorder-related blood-pressure condition. StockAnalysis U.S. stock markets are closed on Thursday for New Year’s Day, leaving investors to digest the regulatory setback before trading resumes on Jan. 2. MarketWatch The decision matters because relacorilant was pitched as Corcept’s next growth driver beyond its existing Cushing’s franchise, and the FDA’s action resets expectations for when — or whether — the drug
AbbVie stock ends 2025 lower as markets shut for New Year — what ABBV investors watch next

AbbVie stock ends 2025 lower as markets shut for New Year — what ABBV investors watch next

NEW YORK, January 1, 2026, 15:38 ET — Market closed AbbVie Inc. shares last closed down 0.5% at $228.49 on Wednesday, the final U.S. trading session of 2025, with Wall Street closed on Thursday for the New Year’s Day holiday. Reuters The market closure matters because AbbVie and other large-cap drugmakers often act as a defensive trade when investors reassess risk at the start of a new year. With liquidity returning in the next session, traders will be watching whether late-December selling pressure persists. Reuters U.S. stocks ended lower on Wednesday, with the S&P 500 down 0.74%, the Nasdaq off
Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

NEW YORK, January 1, 2026, 10:21 ET — Market closed Eli Lilly shares slipped 0.5% in Wednesday’s final session of 2025, closing at $1,074.68, before U.S. markets shut for the New Year’s Day holiday. StockAnalysis+1 Why it matters now: drugmakers typically reset U.S. list prices at the start of the year, and new data have put the industry’s pricing playbook back under a political microscope. Reuters reported drugmakers plan to raise list prices on at least 350 branded medicines in 2026, even as they cut prices on a handful of drugs. Reuters Lilly sits at the center of two investor
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance The year-end move keeps focus on the company’s pivot from clinical-stage developer to commercial operator, with investors looking for hard signals on pricing and early demand. For drug developers, the first few weeks of launch execution can reset expectations quickly. Cytokinetics has said Myqorzo is expected
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 06:48 ET — Market closed Pfizer Inc shares were last indicated slightly lower after hours on Wednesday after a report said the drugmaker plans to raise U.S. list prices on about 80 medicines in 2026. U.S. stock markets were closed on Thursday for the New Year’s Day holiday. (Reuters) Why it matters now: January is the industry’s main reset point for annual drug pricing, and the moves land as Washington keeps drug costs in the political crosshairs. Investors often read fresh price actions as both a revenue lever and a regulatory risk flag. The headline
Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

Pfizer stock today: PFE in focus as 2026 U.S. drug price hikes kick off — what to watch next

NEW YORK, January 1, 2026, 05:20 ET — Market closed. Pfizer Inc (NYSE:PFE) is in focus after annual U.S. drug pricing changes for 2026 included increases on some of its medicines, a politically sensitive topic heading into the new year. Pfizer shares last closed down 0.36% at $24.90 on Wednesday after trading between $24.88 and $25.02, with about 29.4 million shares changing hands. The price resets typically arrive on Jan. 1, when manufacturers post higher list prices — the sticker price before rebates — for many branded drugs. This year’s round is landing as the Trump administration keeps pressure on
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

NEW YORK, January 1, 2026, 04:59 ET — Market closed Outlook Therapeutics, Inc. (Nasdaq: OTLK) shares fell sharply in after-hours trading on Dec. 31 after the U.S. Food and Drug Administration again declined to approve its ONS-5010/LYTENAVA (bevacizumab-vikg) filing for wet age-related macular degeneration. The stock closed down 15.51% at $1.58 and slid to $0.58 after hours. Nasdaq The decision is the third complete response letter the company has received on the application, following earlier FDA letters in August 2023 and August 2025, Ophthalmology Times reported. The drug is already authorized in the European Union and the UK and has
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

NEW YORK, January 1, 2026, 04:13 ET — Market closed Corcept Therapeutics Incorporated shares last closed down 50.4% at $34.80 on Wednesday. Yahoo Finance The selloff followed news that the U.S. drug regulator will not approve relacorilant in its current form for an expanded use tied to a rare hormonal disorder. The decision matters now because relacorilant was the company’s near-term bid to broaden its cortisol-modulation franchise beyond its existing product line, and investors had been bracing for a pivotal regulatory readout into year-end. A setback at the FDA can reset timelines and raise costs, forcing Wall Street to reprice
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

NEW YORK, December 31, 2025, 8:48 PM ET — Market closed Johnson & Johnson (JNJ) shares eked out a 0.02% gain to $206.95 on Wednesday, a rare green finish as U.S. stocks slipped in the final session of 2025. The S&P 500 fell 0.74% and the Dow lost 0.63%. MarketWatch The muted close leaves investors searching for a clean catalyst after a strong year for the stock. The next big read comes when management updates guidance and lays out how recent deals will flow through earnings. That focus sharpened this week after the company said it completed its $3.05 billion
Merck stock dips after hours as 2025 ends; MRK investors shift focus to Feb. 3 earnings

Merck stock dips after hours as 2025 ends; MRK investors shift focus to Feb. 3 earnings

NEW YORK, December 31, 2025, 19:34 ET — After-hours Merck & Co (MRK) shares slipped about 0.7% to $105.26 in after-hours trading on Wednesday, the electronic session after the 4 p.m. close. The stock traded between $104.97 and $106.08 and logged about 7.6 million shares in volume. The late move capped a holiday-shortened week when lighter volume can amplify small swings, especially after the year’s final closing bell. For Merck holders, the calendar matters as much as the tape. Investors are watching how the drugmaker sustains growth beyond Keytruda, its blockbuster cancer drug, as the franchise heads toward a patent
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation

Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation

NEW YORK, December 31, 2025, 19:19 ET — After-hours Axsome Therapeutics, Inc. shares jumped 22.9% to $182.64 in after-hours trading on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental New Drug Application for AXS-05 to treat agitation linked to Alzheimer’s disease and granted it Priority Review. The agency set an April 30, 2026 target action date, and CEO Herriot Tabuteau said “up to 76% of people with Alzheimer’s disease experience agitation.” GlobeNewswire The decision matters because Priority Review shortens the FDA’s review timeline, pulling a key regulatory catalyst forward for investors who have been
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

NEW YORK, December 31, 2025, 18:50 ET — After-hours Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. Reuters The timing
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

NEW YORK, December 31, 2025, 17:16 ET — After-hours Eli Lilly and Co (LLY) shares slipped in after-hours trading on Wednesday. The stock was down about 0.5% at $1,074.68, after trading between $1,074.39 and $1,083.25 during the day on roughly 1.5 million shares. Drug pricing has moved back to the center of the investment case for large-cap pharmaceuticals as Washington pushes for lower costs and companies adjust prices in overseas growth markets. For Lilly, price assumptions matter because investors have priced in years of strong growth from its GLP‑1 franchise, a hormone-based drug class used for diabetes and weight loss.
Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

NEW YORK, December 31, 2025, 14:53 ET — Regular session Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters The planned increases, set to start Jan. 1, land at a sensitive moment for drug pricing as the Trump administration presses the industry to lower costs. Annual list-price resets can also shape negotiations with insurers and the political risk premium investors apply to large drugmakers. Pfizer’s own outlook has put a spotlight on revenue durability. In its December guidance, Pfizer
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

NEW YORK, December 31, 2025, 14:41 ET — Regular session Axsome Therapeutics shares jumped 23% in afternoon trading on Wednesday after the company said U.S. regulators accepted its application and granted a faster review for AXS-05 to treat agitation in Alzheimer’s disease. GlobeNewswire The FDA’s acceptance puts a hard deadline on the next major catalyst for Axsome, with an April 30, 2026 decision target that brings clarity to the company’s regulatory timeline. The stock move also stood out against the broader biotech group, which was modestly higher. GlobeNewswire Axsome said the FDA granted “Priority Review,” meaning the agency’s goal is
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

NEW YORK, December 31, 2025, 13:58 ET — Regular session Shares of Corcept Therapeutics Incorporated (CORT.O) sank nearly 50% on Wednesday after the U.S. Food and Drug Administration issued a complete response letter for the company’s relacorilant application in hypertension secondary to hypercortisolism, also known as Cushing’s syndrome. The stock was down 49.7% at $35.31 in afternoon trading. Nasdaq The decision lands at a sensitive moment for investors who had been looking to relacorilant as the company’s next product story in Cushing’s beyond its marketed therapy. “FDA’s request for additional data may require additional trials, significantly dimming Corcept’s outlook in
Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

Vanda (VNDA) stock jumps 28% after FDA approves Nereus motion-sickness drug

NEW YORK, December 31, 2025, 13:38 ET — Regular session Vanda Pharmaceuticals shares jumped 28.1% to $9.01 at 1:38 p.m. ET on Wednesday after the company said the U.S. Food and Drug Administration approved Nereus (tradipitant) to prevent vomiting induced by motion. Vanda said the oral drug is a neurokinin-1 (NK-1) receptor antagonist — meaning it blocks a receptor involved in nausea signaling — and called it the first new pharmacologic motion-sickness treatment in more than four decades. In late-stage Phase 3 trials — the final stage before approval — vomiting rates were about 10%–20% on Nereus versus 38%–44% on
31 December 2025
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

NEW YORK, December 31, 2025, 13:48 ET — Regular session Eli Lilly shares edged lower on Wednesday as investors weighed new signals that blockbuster diabetes and obesity drugs are heading into 2026 with lower price tags in some markets. The stock was down 0.1% at $1,078.95 by 1:48 p.m. ET, after trading between $1,076.86 and $1,083.25. The pricing debate matters for Lilly because its growth story is dominated by GLP-1 drugs, a class of diabetes and obesity treatments that mimic a gut hormone to curb appetite and lower blood sugar. Moves that broaden access can lift volumes, but price cuts
Lupin delays VISUfarma close date, doubles down on India obesity-drug push

Lupin delays VISUfarma close date, doubles down on India obesity-drug push

NEW YORK, Dec 31, 2025, 1:25 ET Lupin said the closing timeline for its acquisition of Dutch eye-care company VISUfarma has been extended, with the transaction now expected to be completed by Feb. 28, 2026. MarketScreener The delay matters because Lupin has pitched VISUfarma as a pillar of its specialty strategy in Europe, and the revised date pushes the deal past the company’s earlier goal of closing by the end of 2025. Lupin Lupin said the VISUfarma transaction is progressing and remains subject to customary closing conditions. Samco VISUfarma, based in the Netherlands, would be acquired through Lupin’s wholly owned
31 December 2025
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

NEW YORK, December 31, 2025, 11:38 ET — Regular session Genmab A/S (GMAB) shares slid on Wednesday, down about 3.3% at $30.44 in New York trading, as investors weighed a late-stage pipeline cut and the closing steps of a major acquisition. The Nasdaq-listed ADR touched $30.36 after opening at $31.42. Genmab said on Dec. 29 it will discontinue further clinical development of acasunlimab following a portfolio review and said the move does not change its full-year 2025 financial guidance. “Although the data have been encouraging, the compelling opportunities we see in our late‑stage pipeline led us to focus our investments,”
1 15 16 17 18 19 34

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop